Facebook Instagram X-twitter Linkedin Youtube Spotify Apple

Clinical Trials

For a quick look at enrolling or soon to be enrolling investigational drug studies in Duchenne and their enrollment criteria, check out our Clinical Trial Cheat Sheet below.
Clinical Trial Cheat Sheet

Clinical Trial Finder

Use this Clinical Trial Finder below that can help provide you with more information regarding clinical trials in Duchenne that that you, your child, or your patient may be eligible for!

Watch Jett Foundation's Mini Satellite Presentation

Emerging Therapies for Duchenne Muscular Dystrophy

Presented by Jean Mah, M.D., Associate Professor of Pediatric Neurology Alberta Children’s Hospital at the 2016 Child Neurology Society Meeting to learn more about these potential therapies!

Latest Duchenne News

July 24, 2026

Satellos Shares Updates from Phase 2 TRAILHEAD Study of SAT-3247 at International Congress on Neuromuscular Diseases (ICNMD)

Satellos recently attended the International Congress on Neuromuscular Diseases (ICNMD) in Florence, Italy (July 7–11), where they presented six-month interim data from their ongoing TRAILHEAD clinical study evaluating SAT-3247 in...
Read More
July 22, 2026

Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)

  On July 20, Dyne Therapeutics announced that the FDA has accepted for review the Biologics License Application (BLA) for zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) for the treatment...
Read More
July 14, 2026

Avidity Shares Community Letter on Submission of Application to FDA Seeking Approval of Delpacibart Zotadirsen Treatment for Duchenne muscular dystrophy Who Have Genetic Variant that May be Treated Through Exon 44 Skipping

On June 25, 2026, Avidity Biosciences, Inc. shared that they have submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of delpacibart zotadirsen (also known as...
Read More
July 10, 2026

Preparing for the Deramiocel FDA Advisory Committee Meeting: How to Submit Written Testimony

The FDA has scheduled an Advisory Committee meeting for July 29, 2026 to review Deramiocel, Capricor’s investigational cell therapy for Duchenne muscular dystrophy. The meeting will be held in person with the...
Read More
July 3, 2026

Sarepta Shares Community Letter and Release Sarepta Announces FDA for Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®

On June 30, 2026, Sarepta Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Applications (sNDAs) for AMONDYS 45® (casimersen)...
Read More
July 3, 2026

Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy

On June 29, 2026, Satellos Bioscience Inc., announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SAT-3247 for the treatment of Duchenne. Please read...
Read More